Cargando…
Targeting immune checkpoints in malignant glioma
Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351697/ https://www.ncbi.nlm.nih.gov/pubmed/27756892 http://dx.doi.org/10.18632/oncotarget.12702 |
_version_ | 1782514816741539840 |
---|---|
author | Zhang, Xuhao Zhu, Shan Li, Tete Liu, Yong-Jun Chen, Wei Chen, Jingtao |
author_facet | Zhang, Xuhao Zhu, Shan Li, Tete Liu, Yong-Jun Chen, Wei Chen, Jingtao |
author_sort | Zhang, Xuhao |
collection | PubMed |
description | Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors. Although once considered immune privileged and devoid of normal immunological functions, CNS is now considered a promising target for cancer immunotherapy, featuring the recent progresses in neurobiology and neuroimmunology and a highly immunosuppressive state in malignant glioma. In this review, we focus on immune checkpoint inhibitors, specifically, antagonizing monoclonal antibodies for programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and indoleamine 2,3-dioxygenase (IDO). We discuss advances in the working mechanisms of these immune checkpoint molecules, their status in malignant glioma, and current preclinical and clinical trials targeting these molecules in malignant glioma. |
format | Online Article Text |
id | pubmed-5351697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53516972017-04-13 Targeting immune checkpoints in malignant glioma Zhang, Xuhao Zhu, Shan Li, Tete Liu, Yong-Jun Chen, Wei Chen, Jingtao Oncotarget Review Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors. Although once considered immune privileged and devoid of normal immunological functions, CNS is now considered a promising target for cancer immunotherapy, featuring the recent progresses in neurobiology and neuroimmunology and a highly immunosuppressive state in malignant glioma. In this review, we focus on immune checkpoint inhibitors, specifically, antagonizing monoclonal antibodies for programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and indoleamine 2,3-dioxygenase (IDO). We discuss advances in the working mechanisms of these immune checkpoint molecules, their status in malignant glioma, and current preclinical and clinical trials targeting these molecules in malignant glioma. Impact Journals LLC 2016-10-16 /pmc/articles/PMC5351697/ /pubmed/27756892 http://dx.doi.org/10.18632/oncotarget.12702 Text en Copyright: © 2017 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Zhang, Xuhao Zhu, Shan Li, Tete Liu, Yong-Jun Chen, Wei Chen, Jingtao Targeting immune checkpoints in malignant glioma |
title | Targeting immune checkpoints in malignant glioma |
title_full | Targeting immune checkpoints in malignant glioma |
title_fullStr | Targeting immune checkpoints in malignant glioma |
title_full_unstemmed | Targeting immune checkpoints in malignant glioma |
title_short | Targeting immune checkpoints in malignant glioma |
title_sort | targeting immune checkpoints in malignant glioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351697/ https://www.ncbi.nlm.nih.gov/pubmed/27756892 http://dx.doi.org/10.18632/oncotarget.12702 |
work_keys_str_mv | AT zhangxuhao targetingimmunecheckpointsinmalignantglioma AT zhushan targetingimmunecheckpointsinmalignantglioma AT litete targetingimmunecheckpointsinmalignantglioma AT liuyongjun targetingimmunecheckpointsinmalignantglioma AT chenwei targetingimmunecheckpointsinmalignantglioma AT chenjingtao targetingimmunecheckpointsinmalignantglioma |